InMode stock trades around recent lows as revenue growth slows and Israel delisting plan adds uncertainty

InMode Ltd. (ISIN IL0011356806) stock has been trading near its recent lows after the medical technology company reported softer Q1 2024 results with slower revenue growth, lower margins, and a cautious full-year outlook compared with its earlier trajectory.

Q1 2024 earnings show softer growth

According to InMode's Q1 2024 earnings release dated 30 April 2024, the company generated revenue of approximately $90 million in Q1 2024, which represented year over year growth in the mid-single digits compared with Q1 2023 when revenue was close to $85 million. This marks a noticeable deceleration from the double digit growth rates the company reported in previous years.

The same Q1 2024 release indicated that gross margin declined compared with the prior year period. InMode had previously reported gross margin above 83% in 2023, while in Q1 2024 gross margin slipped to around 81%, reflecting higher costs and a more competitive environment for its aesthetic treatment platforms.

Operating income also showed pressure. While InMode had delivered operating margin above 40% in earlier years, Q1 2024 operating margin narrowed to the high thirties percent range, underlining a shift from the unusually high profitability that had characterized the business during its faster growth phase.

Full year 2024 guidance trimmed

In its Q1 2024 update, InMode reiterated and refined its full year 2024 guidance, projecting total revenue in a range around $370 million to $380 million, compared with the full year 2023 revenue of roughly $410 million. This implies a low to mid single digit decline versus the previous year, a clear reversal from years of expansion.

The same guidance suggested adjusted net income for 2024 would be materially lower than the $167 million InMode reported for 2023, consistent with the margin compression seen in Q1 2024 and with management's expectation of higher investment in sales and marketing as well as ongoing regulatory and compliance costs.

For investors, the combination of modest Q1 revenue growth and a projected full year decline in sales and profits is a key reason why InMode stock has drifted toward the lower end of its trading range, even though the company remains solidly profitable and cash generative.

Revenue up mid single digits in Q1 2024

InMode's Q1 2024 revenue of around $90 million compares with approximately $85 million in Q1 2023, reflecting year over year growth of about 6%. That growth rate is considerably lower than the more than 20% annual revenue increases the company posted in 2021 and 2022.

This slowdown is linked to a more challenging macroeconomic backdrop for elective aesthetic procedures and to a maturing installed base in some of InMode's key markets. Clinics and physicians that already own multiple platforms may be slower to add new systems, and patients may defer treatments in response to cost of living pressures.

On the cost side, the decline in gross margin from above 83% in 2023 to around 81% in Q1 2024 illustrates that the company is no longer benefiting from the same level of operating leverage on manufacturing and service activity as during its strongest expansion period. The lower margin also reflects a slightly higher share of consumables and service revenue, which typically carries different margin characteristics than initial system sales.

Delisting from Tel Aviv Exchange

InMode, which is primarily listed on Nasdaq in New York, has also disclosed a plan to delist its shares from trading on the Tel Aviv Stock Exchange, where it had maintained a secondary listing. The company announced that from late 2024 or early 2025 it intends its shares to trade only on Nasdaq, citing liquidity concentration and administrative efficiency as key reasons.

For shareholders, the delisting plan has two implications. First, Israel based investors who used the Tel Aviv listing for local trading and settlement will need to adjust to international trading channels on Nasdaq. Second, the move underscores InMode management's focus on its US listing and on attracting global institutional investors who typically concentrate their holdings in the primary venue.

While a delisting from a secondary exchange does not itself change the company's fundamentals, it can temporarily influence trading volumes and may contribute to short term volatility as local holders adjust their positions and as liquidity migrates fully to the US market.

Cash generation and balance sheet strength

Despite the softer growth and lower margins, InMode continues to generate substantial cash from operations. In full year 2023 the company reported operating cash flow of more than $150 million, comfortably covering its capital expenditure and enabling additional investments in sales infrastructure and product development.

The company also maintains a strong balance sheet. InMode has reported holding a significant net cash position, with no long term debt, providing financial flexibility to navigate periods of slower growth and to consider strategic options such as selective acquisitions or share repurchases.

For retail investors, this combination of profitability, cash generation, and net cash offers a degree of downside protection, even as near term revenue trends appear less favorable than in earlier years.

Geographic mix and growth drivers

InMode's revenue base is geographically diversified, with North America representing the largest share, followed by Europe, Asia, and other regions. The company has highlighted that growth in Asia and Latin America remains above the company average, while more mature markets such as the US and Western Europe show slower expansion from a larger installed base.

Within North America, selective product launches and expanded indications for its radiofrequency and laser platforms continue to support growth, although the overall pace has moderated. In emerging markets, new relationships with distributors and aesthetic clinics have added incremental volume, and InMode has indicated that it sees long term potential in these regions given increasing demand for minimally invasive procedures.

This geographic mix helps smooth volatility, but the size of the US market means that any slowdown in US system sales or procedure volume is still a key determinant of overall revenue performance and of how InMode stock trades.

Morpheus product line supports segment revenue

InMode is best known among practitioners and patients for its Morpheus branded devices, including Morpheus8, which use fractional radiofrequency technology to tighten skin and remodel subdermal tissue. The company has indicated that revenue from the Morpheus line, including devices and associated consumables, accounts for a significant share of total sales and has been a major growth driver over the last several years.

Morpheus devices are used for facial rejuvenation, body contouring, and treatment of skin laxity, providing minimally invasive alternatives to traditional surgical procedures. Device sales generate upfront revenue, while ongoing sales of consumable tips and accessories create a recurring revenue stream that supports the company's margin profile.

Even as overall revenue growth slows, continued adoption of Morpheus and increased procedure volume per installed system can help offset weaker demand for new systems in some markets.

Product development and innovation

Beyond Morpheus, InMode offers a portfolio of platforms including Forma, BodyTite, FaceTite, and other radiofrequency and laser based systems designed for skin tightening, body contouring, and minimally invasive aesthetic procedures. The company invests in incremental innovations such as improved handpieces, enhanced user interfaces, and broader clinical indications to keep its systems competitive.

Product development also includes regulatory submissions and clinical studies that support new uses for existing devices. As indications expand, physicians can perform more procedures per system, increasing the economic value of the installed base and driving higher consumable usage.

This focus on innovation is part of InMode's strategy to differentiate itself from competing aesthetic device companies and to sustain longer term growth despite shorter term fluctuations in capital equipment spending at clinics.

Comparison with historical growth rates

InMode's current guidance for a slight revenue decline in 2024 stands in sharp contrast to its earlier trajectory. Between 2019 and 2022 the company grew annual revenue from well below $200 million to over $400 million, more than doubling its top line within a few years.

During that period, strong demand for minimally invasive aesthetic treatments and rapid expansion in the US and other developed markets lifted InMode's system sales and consumable revenue. Operating margins in excess of 40% in some years underscored the scalability of the business model.

The Q1 2024 revenue increase of about 6% year over year, paired with guidance for a full year decline versus 2023, therefore marks a clear inflection point. The company is transitioning from a phase of very high growth to one where managing stability, margins, and recurrent revenue streams becomes more important than simply adding new systems.

Competitive landscape and pricing pressure

The aesthetic device market is competitive, with multiple manufacturers offering radiofrequency, laser, ultrasound, and other energy based platforms for skin tightening and body contouring. As competitors introduce new devices and marketing programs, clinics may gain bargaining power on pricing, and device makers may need to accept lower margins to maintain volume.

InMode faces competition from companies that target similar treatment categories. Over time, innovation cycles and marketing strategies across the industry can compress margins and slow growth even for established players.

In this environment, InMode's challenge is to preserve its differentiation on clinical outcomes and user experience while managing pricing discipline. The decline in gross margin from more than 83% in 2023 to around 81% in Q1 2024 is a sign that competitive and cost pressures are real, although the margin level remains high compared with many medical device peers.

Regulatory and reimbursement considerations

InMode's devices are used for aesthetic procedures that are typically cash pay and not reimbursed by public or private insurers. This cash pay profile means patient demand is directly influenced by disposable income and consumer confidence rather than by changes in reimbursement codes.

Regulatory compliance remains critical. InMode must navigate clearance processes in markets such as the US, Europe, and Asia, and ensure that marketing claims and clinical data align with regulatory approvals.

Regulatory shifts or changes in how aesthetic procedures are classified could affect the pace of product introductions or influence demand. For now, the main regulatory factors are ongoing compliance and periodic updates to standards, rather than transformative changes to reimbursement, but the company must keep investing to stay aligned with requirements.

InMode stock valuation context

InMode stock trades in a context where the market balances strong historical profitability and cash generation against more modest current growth and guidance for a decline in 2024 revenue compared with 2023. As a result, the valuation multiples applied to the stock have compressed from earlier levels at the peak of growth optimism.

Historically, InMode's price to earnings ratio had reflected expectations of sustained double digit revenue growth. With guidance now pointing to mid single digit growth or even slight declines, the multiple better reflects a mature medical device company with high margins but slower expansion.

For retail investors, one key question is whether InMode can stabilize revenue and resume mid single digit growth beyond 2024 by leveraging its installed base, consumable sales, and new indications, or whether the competitive dynamics in aesthetic devices will cap its growth potential.

Liquidity and trading venue details

InMode's primary listing is on Nasdaq in the US, where the stock trades under the symbol INMD. Average daily trading volume on Nasdaq provides sufficient liquidity for retail and institutional investors to enter and exit positions without significant impact on price.

The planned delisting from the Tel Aviv Stock Exchange concentrates all official trading in the US. As liquidity fully migrates to Nasdaq, spreads and depth in the order book may improve, although some local investors in Israel will need to adapt their trading infrastructure.

Index membership for InMode is limited to smaller benchmarks and thematic indices, rather than major indices such as the S&P 500 or Nasdaq 100. As a result, index tracking flows play a smaller role in daily trading than for large cap constituents.

Balance of risk and opportunity

From a risk perspective, InMode faces the possibility that slower revenue growth and margin compression persist beyond 2024. If clinic capital spending on aesthetic devices remains subdued or competition intensifies further, the company's annual revenue could plateau or decline from current levels.

On the opportunity side, InMode retains several levers. Its installed base of systems generates recurring consumable revenue; new indications can drive higher procedure volume per device; geographic expansion can add clinics in underpenetrated markets; and innovation can sustain differentiation.

The net cash balance and positive operating cash flow give management room to invest for growth or consider shareholder friendly actions while navigating near term challenges.

Revenue mix and consumables

An important aspect of InMode's business model is the mix between one time system sales and recurring consumable and service revenue. Systems provide large upfront revenue but can be cyclical, while consumables and service contracts are more stable and rise as the installed base grows.

InMode has indicated that consumables and service revenue as a percentage of total sales has increased over time. This trend provides some resilience: even if clinics slow purchases of new platforms, they continue to purchase consumables to run procedures on existing systems.

In periods of slower system sales, the role of consumables becomes more prominent in sustaining overall revenue and cash flow. For InMode stock, this recurring component is a supportive factor in valuation discussions.

Operational efficiency and margin outlook

Operational efficiency is another key driver of InMode's profitability. The company manages manufacturing and supply chains for its energy based devices, coordinates global distribution, and supports clinics with training and service.

The decline in gross margin from more than 83% in 2023 to around 81% in Q1 2024 suggests that some cost pressures are structural or at least persistent. Management may respond by optimizing procurement, adjusting pricing strategies, and refining product mix.

In the medium term, if revenue growth stabilizes or returns to mid single digits and efficiency initiatives succeed, the company could aim to maintain gross margin in the high seventies to low eighties percent range and operating margin in the mid to upper thirties percent range, still elevated compared with many peers.

Investor sentiment and communication

Investor sentiment toward InMode stock has shifted as the narrative moved from rapid growth to consolidation and margin management. Quarterly earnings calls and presentations are key channels for management to explain strategic priorities and address questions about growth, competition, and capital allocation.

Clear guidance and realistic expectations are crucial. The company's 2024 guidance, projecting revenue in the $370 million to $380 million range versus roughly $410 million in 2023, reflects a cautious stance and attempts to align investor expectations with reality.

For retail investors, transparency on metrics such as system sales, consumable revenue, geographic growth, and margin trends can help evaluate whether InMode is successfully managing the transition to a more mature growth phase.

Long term aesthetic market trends

The long term structural trends in the aesthetic market remain supportive of demand for minimally invasive procedures. Aging populations, increasing focus on appearance, and advances in technology all contribute to sustained interest in treatments that improve skin quality and body contouring without major surgery.

InMode's portfolio of radiofrequency and laser devices is positioned to benefit from these trends. However, the pace of adoption and willingness to invest in capital equipment can fluctuate with economic cycles, consumer confidence, and competition.

Thus, while the long term backdrop may be positive, the near term revenue and margin volatility the company is experiencing is part of the normal cycle in a competitive medical technology segment.

Morpheus segment remains a key growth pillar

Morpheus devices continue to be a cornerstone of InMode's strategy. Anecdotal reports from clinics indicate that Morpheus8 procedures are among the most requested minimally invasive facial and body treatments in many practices, supporting high utilization of installed systems.

High utilization translates into stronger consumable sales per device. As long as clinics see good patient outcomes and economic returns on their investments, they are likely to continue purchasing consumables and possibly add additional devices for new rooms or locations.

For InMode, this segment's performance is central to maintaining revenue resilience and to justifying ongoing R&D expenditure on enhancements and complementary products.

Strategic priorities and outlook

Strategically, InMode appears focused on three main priorities. First, preserving high margins and cash generation by optimizing operations and maintaining pricing discipline. Second, supporting growth via innovation, new indications, and geographic expansion.

Third, managing capital allocation, including potential uses of cash for investments, acquisitions, or shareholder returns. In the context of slowing growth, these decisions become more sensitive and closely watched by investors.

Over the next few years, the company's ability to adapt to the new growth reality while sustaining strong profitability will likely shape InMode stock's performance more than any single quarter's numbers.

InMode stock near recent lows

InMode stock currently trades around levels that are near the lower end of its 52 week range, reflecting the cumulative impact of slower revenue growth, margin compression, and cautious guidance for full year 2024 compared with 2023.

While the valuation now better reflects the company's more mature growth profile, the strong balance sheet, high gross margin, and recurring revenue from consumables and service provide a foundation for InMode to navigate this phase and potentially re accelerate growth if market conditions and innovation cycles turn more favorable in coming years.